BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33890815)

  • 21. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Relationships between HER2 Overexpression and DCIS Characteristics.
    Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
    Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
    Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
    J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel Node Biopsy in Early Breast Cancer Patients with Palpable Axillary Node.
    Shojaee L; Abedinnegad S; Nafisi N; Naghshvar F; Godazandeh G; Moradi S; Shakeri Astani K; Godazandeh Y
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1631-1636. PubMed ID: 32592357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
    Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
    Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
    Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
    J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
    Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
    Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Axillary Assessment of Ductal Carcinoma In Situ of the Breast Necessary in All Cases?
    Bellver G; Buch E; Ripoll F; Adrianzen M; Bermejo B; Burgues O; Julve A; Ortega J
    J Surg Res; 2022 Mar; 271():145-153. PubMed ID: 34902737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component.
    Wasserberg N; Morgenstern S; Schachter J; Fenig E; Lelcuk S; Gutman H
    Arch Surg; 2002 Nov; 137(11):1249-52. PubMed ID: 12413311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study.
    Li Y; Zhang S; Wei X; Zhang J
    Int J Surg; 2015 Jul; 19():91-4. PubMed ID: 26013173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
    Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
    Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic "Ductal Carcinoma In Situ-Like" Lobular Carcinoma in a Lymph Node: A Case Report and Review of the Literature.
    Tijani S; Sharma K; Yuen H; Shaaban A
    Int J Surg Pathol; 2020 Jun; 28(4):436-439. PubMed ID: 31789065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once.
    Hotton J; Salleron J; Rauch P; Buhler J; Pierret M; Baumard F; Leufflen L; Marchal F
    J Gynecol Obstet Hum Reprod; 2020 Mar; 49(3):101641. PubMed ID: 31562936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
    Tunon-de-Lara C; Giard S; Buttarelli M; Blanchot J; Classe JM; Baron M; Monnier B; Houvenaeghel G
    Breast J; 2008; 14(2):135-40. PubMed ID: 18315691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.